Back to News
Market Impact: 0.2
Alaunos Therapeutics Consensus Price Target Increased by 7,400% to $267.75
Source: Nasdaq
Analyst EstimatesAnalyst Insights
Fintel’s aggregate one-year analyst price target for Alaunos Therapeutics was revised to $267.75 per share, up 7,400% from the prior estimate of $3.57 dated August 1, 2023. The article text is truncated and provides no explanation for the revision or evidence of a market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
TCRT0.10
More News
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- Reliance’s Record $19 Billion Surge Lifts Nifty, Keeps India Bulls in the Game
- Apple reports after the bell. Options traders expect a big move
- Mizuho lowers Lumentum stock price target on Marvell acquisition
- Why is Apple stock falling afterhours today?
- RA Capital Management sells $9.13M in Lenz Therapeutics shares